Clinical Data Novo may have muscle advantage over Lilly in weight-loss race: preprint pharminent April 17, 2026
Regulatory Replimune cries foul on regulatory flexibility. But many Americans want a stricter FDA pharminent April 17, 2026
M&A / Deals Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions pharminent April 17, 2026
M&A / Deals Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions pharminent April 17, 2026
Policy / Pricing Erica Schwartz, ex-deputy surgeon general, picked to be next CDC director pharminent April 16, 2026
Clinical Data Lilly’s new obesity pill passes heart safety test in diabetes pharminent April 16, 2026
Clinical Data Lilly debuts more Foundayo data as FDA requests post-marketing trials pharminent April 16, 2026
Clinical Data Roche to start new Elevidys study following setback in Europe pharminent April 16, 2026
Clinical Data Lilly’s Foundayo posts ‘outstanding’ diabetes data, possibly easing FDA safety concerns pharminent April 16, 2026
M&A / Deals Obesity’s explosive growth continues as Q1 deals exceed total 2025 value pharminent April 16, 2026
Policy / Pricing FDA accelerated approval path needs improvement, says ICER pharminent April 16, 2026
Commercial Revolution doubles stock offering target to $2B following pancreatic cancer win pharminent April 16, 2026
M&A / Deals Terremoto wins $108m in Series C to drive cancer and rare disease programmes pharminent April 16, 2026
Clinical Data Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study pharminent April 16, 2026
Clinical Data Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study pharminent April 16, 2026
M&A / Deals Beeline, a Bain-backed biotech, debuts with immune drugs from Bristol Myers pharminent April 15, 2026
Regulatory FDA Approves Extended Dosing Interval for Regeneron’s EYLEA HD (aflibercept) pharminent April 15, 2026
Regulatory Lilly’s new obesity pill linked to ‘serious’ safety signals, FDA requests more data pharminent April 15, 2026
M&A / Deals Takeda continues to prune partnerships, cuts ties with mRNA-targeting Veritas In Silico pharminent April 15, 2026
M&A / Deals BMS makes a Beeline, bringing 5 assets to biotech’s $300M precision immunology debut pharminent April 15, 2026
